These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 16473413)

  • 1. Cytokine responses to EHV-1 infection in immune and non-immune ponies.
    Coombs DK; Patton T; Kohler AK; Soboll G; Breathnach C; Townsend HG; Lunn DP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):109-16. PubMed ID: 16473413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies.
    Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
    Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC
    Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection.
    Paillot R; Ellis SA; Daly JM; Audonnet JC; Minke JM; Davis-Poynter N; Hannant D; Kydd JH
    Vaccine; 2006 Mar; 24(10):1490-500. PubMed ID: 16269205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equine herpesvirus-1 infection induces IFN-gamma production by equine T lymphocyte subsets.
    Breathnach CC; Soboll G; Suresh M; Lunn DP
    Vet Immunol Immunopathol; 2005 Feb; 103(3-4):207-15. PubMed ID: 15621307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus.
    Holmes MA; Townsend HG; Kohler AK; Hussey S; Breathnach C; Barnett C; Holland R; Lunn DP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):67-80. PubMed ID: 16476488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and phenotype of EHV-1 specific, IFN-gamma synthesising lymphocytes in ponies: the effects of age, pregnancy and infection.
    Paillot R; Daly JM; Luce R; Montesso F; Davis-Poynter N; Hannant D; Kydd JH
    Dev Comp Immunol; 2007; 31(2):202-14. PubMed ID: 16824599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1.
    Paillot R; Daly JM; Juillard V; Minke JM; Hannant D; Kydd JH
    Vaccine; 2005 Aug; 23(36):4541-51. PubMed ID: 15913852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-mediated immunity evaluation in foals infected with virulent equine herpesvirus-1 by multi-parameter flow cytometry.
    Platt R; Sponseller BA; Chiang YW; Roth JA
    Vet Immunol Immunopathol; 2010 Jun; 135(3-4):275-81. PubMed ID: 20116862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection of peripheral blood mononuclear cells with neuropathogenic equine herpesvirus type-1 strain Ab4 reveals intact interferon-α induction and induces suppression of anti-inflammatory interleukin-10 responses in comparison to other viral strains.
    Wagner B; Wimer C; Freer H; Osterrieder N; Erb HN
    Vet Immunol Immunopathol; 2011 Sep; 143(1-2):116-24. PubMed ID: 21764140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One way protection between equid herpesvirus 1 and 4 in vivo.
    Edington N; Bridges CG
    Res Vet Sci; 1990 Mar; 48(2):235-9. PubMed ID: 2159176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inoculation of mares and very young foals with EHV-1 glycoproteins D and B reduces virus shedding following respiratory challenge with EHV-1.
    Foote CE; Raidal SL; Pecenpetelovska G; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2006 May; 111(1-2):97-108. PubMed ID: 16504306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity.
    Schnabel CL; Wimer CL; Perkins G; Babasyan S; Freer H; Watts C; Rollins A; Osterrieder N; Wagner B
    BMC Vet Res; 2018 Aug; 14(1):245. PubMed ID: 30134896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of immune responses following infection of ponies with an EHV-1 ORF1/2 deletion mutant.
    Soboll Hussey G; Hussey SB; Wagner B; Horohov DW; Van de Walle GR; Osterrieder N; Goehring LS; Rao S; Lunn DP
    Vet Res; 2011 Feb; 42(1):23. PubMed ID: 21314906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.
    Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
    Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
    Van de Walle GR; May MA; Peters ST; Metzger SM; Rosas CT; Osterrieder N
    Vaccine; 2010 Jan; 28(4):1048-55. PubMed ID: 19897066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of equine herpesvirus-specific effector and memory cytotoxic immunity in the equine upper respiratory tract.
    Breathnach CC; Yeargan MR; Timoney JF; Allen GP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):117-25. PubMed ID: 16472871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges.
    Patel JR; Földi J; Bateman H; Williams J; Didlick S; Stark R
    Vet Microbiol; 2003 Mar; 92(1-2):1-17. PubMed ID: 12488066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.
    Paillot R; Kydd JH; Sindle T; Hannant D; Edlund Toulemonde C; Audonnet JC; Minke JM; Daly JM
    Vet Immunol Immunopathol; 2006 Aug; 112(3-4):225-33. PubMed ID: 16621023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.